FDA Expands Pluvicto’s Metastatic Castration-Resistant Prostate Cancer Indication

The FDA expanded the indication for(Pluvicto to include adults with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with ARPI therapy and are considered appropriate to delay taxane-based chemotherapy.